Lifeboat Foundation

Glioblastoma is one of the most aggressive types of brain cancer known to man. For many, the chance of survival is often low. However, a new type of brain tumor therapy could help change things for the better. The therapy, which relies on destroying the “power source” of the cancer, has shown considerable success in mice. The scientists are hopeful it will work the same in humans.

The new therapy hopes to destroy the “power source” of glioblastoma tumors. A new study led by Israeli scientists shows that glioblastoma relies on specific brain cells to fuel the growth of its tumors. As a result, scientists began to look at ways to treat cancer by removing those cells instead. The new brain tumor therapy could completely starve out the cancer cells, allowing patients to enter remission.

Normally doctors would use chemotherapy to target the tumors directly. However, by removing brain cells called Astrocytes, scientists found they could starve out glioblastoma tumors in mice. Further, the tumors remained gone for as long as the astrocytes were repressed. And, even when they stopped suppressing, Dr. Lior Mayo, lead author on the study, says that 85 percent of mice stayed in remission.

Shared biology between Language, Reading, and Writing discovered! Abstract in the youtube description.

What We Owe The Future is available now — you can get it wherever you get your (audio)books or here: https://www.amazon.com/What-Owe-Future-William-MacAskill/dp/…atfound-20
This video was sponsored by the author, Will MacAskill. Thanks a lot for the support.

Sources & further reading:
https://sites.google.com/view/sources-civilization-collapse/

Continue reading “Is Civilization on the Brink of Collapse?” »

Leonel Malacrida hopes that his lab’s imaging technology will advance cancer diagnosis and research in Uruguay and across Latin America.

Did they unlock one of the vital keys to stop aging?

According to a recent National Eye Institute (NEI) study in mice, loss of the protein pigment epithelium-derived factor (PEDF), which protects retinal support cells, may promote age-related changes in the retina.

Age-related retinal diseases, such as age-related macular degeneration (AMD), can cause blindness since the retina is the light-sensitive tissue at the back of the eye. The new information could help develop medicines to stop AMD and other aging conditions of the retina. The research was published in the International Journal of Molecular Sciences. NEI is part of the National Institutes of Health.

Continue reading “Scientists Find That the Loss of a ‘Youth’ Protein Could Drive Aging” »

Amazon is having to curtail growth of its vast delivery network which exploded in size during the pandemic.

Dr Vittorio Sabastiano explains the possibilities on resetting the age of any cell type in the near future in this clip.

Dr. Vittorio Sebastiano is an Assistant Professor in the Department of Obstetrics and Gynecology at Stanford School of Medicine. His lab has established a new technology named ERA (Epigenetic Reprogramming of Aging), which repurposes the conceptual idea of reprogramming, with the goal to promote epigenetic rejuvenation of adult cells leaving their identity untouched. This new technology was patented and is being implemented by Turn Biotechnologies, of which Dr. Sebastiano is co-founder and Chair of the Scientific Advisory Board.

Continue reading “FOREVER YOUNG — The Peter Pan Case | Dr Vittorio Sabastiano Interview Clips” »

An experimental combination of two drugs halts the progression of small cell lung cancer, the deadliest form of lung cancer, according to a study in mice from researchers at Washington University School of Medicine in St. Louis, Grenoble Alpes University in Grenoble, France, and The University of Texas MD Anderson Cancer Center in Houston.

One of the drugs, cyclophosphamide, is an outdated chemotherapy drug once used to treat small cell lung cancer. It was displaced in favor of platinum-based drugs in the 1980s. Both kinds of drugs work at first but falter after a few months as the cancer develops resistance. Platinum-based drugs became the standard of care mainly because they cause lesser side effects, but they have not substantially improved prognosis. Today, the typical patient survives less than a year and a half after diagnosis.

In this study, however, researchers showed that small cell lung cancer cells resist cyclophosphamide by activating a specific repair process, and demonstrated that throwing a wrench into the repair process makes the drug much more effective, at least in mice. The findings, available online in Cancer Discovery, suggest a pathway to better therapies for one of the least treatable forms of cancer.

The Dunedin Pace of Aging Algorithm (PACE) was created by researchers from Duke, and the University of Otago over the course of 50 years of longitudinal research. It offers a revolutionary way to track aging which looks at an individual’s current rate of aging, and now TruDiagnostic has announced it is offering this powerful, third-generation clock to the public at an affordable price through TruAge PACE.

Longevity. Technology: Biologically, aging is the process of human cells slowly losing function over time; this process can be tracked by examining molecular markers called methylation and using advanced algorithms to sort those markers and calculate a person’s biological age – how old they are biologically rather than they number of birthdays they have clocked up.

The ability to track aging is dependent on the ability of the algorithms themselves. Until recently, most algorithms were trained on chronological age, and this meant they had poor responsiveness to interventions that are known to impact the biological course of aging. PACE gives individuals t he ability to detect rapid aging at an early age.